COLL Collegium Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: COLL

Price (delayed)

$22.37

Market cap

$788.49M

P/E Ratio

18.49

Dividend/share

N/A

EPS

$1.21

Enterprise value

$897.47M

Highlights
Collegium Pharmaceutical's gross profit has surged by 68% YoY and by 9% QoQ
The gross margin has surged by 57% year-on-year and by 6% since the previous quarter
The equity is up by 21% year-on-year but it is down by 9% since the previous quarter
COLL's debt is up by 10% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.collegiumpharma.com/
Peers: HZNP UTHR KMPH

Key stats

What are the main financial stats of COLL
Market
Shares outstanding
35.25M
Market cap
$788.49M
Enterprise value
$897.47M
Valuations
Price to earnings (P/E)
18.49
Price to book (P/B)
4.57
Price to sales (P/S)
2.43
EV/EBIT
12.4
EV/EBITDA
12.2
EV/Sales
2.79
Earnings
Revenue
$321.23M
EBIT
$72.39M
EBITDA
$73.54M
Free cash flow
$114.63M
Per share
EPS
$1.21
Free cash flow per share
$3.28
Book value per share
$4.89
Revenue per share
$9.19
TBVPS
$9.35
Balance sheet
Total assets
$646.07M
Total liabilities
$476.03M
Debt
$294.32M
Equity
$170.04M
Working capital
$66.14M
Liquidity
Debt to equity
1.73
Current ratio
1.29
Quick ratio
1.21
Net debt/EBITDA
1.48
Margins
EBITDA margin
22.9%
Gross margin
61.2%
Net margin
13.1%
Operating margin
22.5%
Efficiency
Return on assets
6.5%
Return on equity
24.5%
Return on invested capital
42.2%
Return on capital employed
17.4%
Return on sales
22.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COLL stock price

How has the Collegium Pharmaceutical stock price performed over time
Intraday
0.36%
1 week
-4.28%
1 month
-2.48%
1 year
23.93%
YTD
11.68%
QTD
-5.61%

Financial performance

How have Collegium Pharmaceutical's revenue and profit performed over time
Revenue
$321.23M
Gross profit
$196.45M
Operating income
$72.36M
Net income
$41.96M
Gross margin
61.2%
Net margin
13.1%
Collegium Pharmaceutical's gross profit has surged by 68% YoY and by 9% QoQ
The gross margin has surged by 57% year-on-year and by 6% since the previous quarter
The net income has soared by 57% from the previous quarter
COLL's net margin has surged by 52% since the previous quarter

Growth

What is Collegium Pharmaceutical's growth rate over time

Valuation

What is Collegium Pharmaceutical stock price valuation
P/E
18.49
P/B
4.57
P/S
2.43
EV/EBIT
12.4
EV/EBITDA
12.2
EV/Sales
2.79
Collegium Pharmaceutical's EPS has soared by 55% from the previous quarter
The equity is up by 21% year-on-year but it is down by 9% since the previous quarter
The price to book (P/B) is 12% lower than the 5-year quarterly average of 5.2 but 11% higher than the last 4 quarters average of 4.1
COLL's price to sales (P/S) is 97% lower than its 5-year quarterly average of 80.3 but 6% higher than its last 4 quarters average of 2.3
The revenue is up by 8% year-on-year and by 3.6% since the previous quarter

Efficiency

How efficient is Collegium Pharmaceutical business performance
The company's return on assets has surged by 55% QoQ
The ROE has soared by 50% QoQ
The ROIC has grown by 24% from the previous quarter
Collegium Pharmaceutical's ROS has increased by 24% from the previous quarter

Dividends

What is COLL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COLL.

Financial health

How did Collegium Pharmaceutical financials performed over time
Collegium Pharmaceutical's total assets is 36% more than its total liabilities
The quick ratio rose by 44% year-on-year and by 11% since the previous quarter
The current ratio has increased by 40% year-on-year and by 11% since the previous quarter
COLL's debt is 73% greater than its equity
The debt to equity rose by 21% QoQ but it fell by 18% YoY
The equity is up by 21% year-on-year but it is down by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.